eli: yes, i think so.he fed is likely to resist a move but i think the fed is not going to react to one data point. if we see cpi print weaker than expected we could do 50. avril: market concerns is about whether we get a hard landing. do think the reaction will be more exacerbated versus anything that shows a soft landing? eli: if we see week data we could go back into a volatility regime but if we ignore the rule it is hard to argue that the u.s. is heading to a recession. corporate earnings are strong. if we look at the labor market there are some segments that is quite resilient and so i think when you get an event it tests assumptions which affect soft landing. that should be the best case. avril: i know you say 50 is not your base case. the other part we have the likes of michelle goldman saying there are upside risk, how much do you think the reserve has? is the market going to force its hand? eli: last two print we have seen inflation on a downtrend. there are upside risks and this next print would

eli lilly has been ramping up supply.expectations will be reset, eli lilly may be better addressing the supply problem short-term than novo nordisk. >> will it be better with mounjaru? >> that would suggest wegovy is on the shortage list. they are better at getting supply in the market, but taking a different approach. wegovy is offered to patients that can continue the trial. whereas lilly products are still dealing with production. >> two new weight-loss drugs coming out next year. one is an oral one. the other may have the most efficacy as all of them. i had to think of the word. r&d, we have gone back and forth they are spending too much. is lilly spending enough with the r &yad? >> looking at the neurological side and eli lilly is an early leader in the oral segment, but they are thinking about other applications with alzheimer's with early trial data that is encouraging. we think as they look at applications beyond weight loss, it will go up. many people are looking at applications beyond weight loss. you have novo

they're getting production of the drugs, but eli lilly is a tough one.tion is coming from everywhere for a whole host of other reasons to prescribe this drug, so, to me, with the valuation, it's kind of hard. maybe novo plays a little catchup. maybe -- >> daily injection that you have to take? >> it's weekly. so, what they're doing is single vials for once a week and they give you the injection. it's weekly with the pen, but that's a really easy thing. you just put a piece of plastic, it tricpricks you a little bit. the issue with the compounds -- >> you have to measure it, get the bubbles out. >> sounds like something i'm going to be doing -- not. i'll say this. i mean, as eli lilly approaches a $1 trillion market cap, which is staggering, we've never seen anything close to that, it's going to force -- we've talked about this, it's going to force other companies to do something, i'm looking at merck, i'm looking at pfizer. but viking therapeutics, which traded lower today in sympathy to the story we just did, they're in the cross hairs, and if you want

eli li eli lilly announcing it will offer low-dosage versions, instead of the pens. patients with a prescription not covered by insurance will be able to buy a month's supply for $399. and the 5-milligram dose for $549, directly from eli lilly. >> we've been frustrated. we can't meet the incredible demand for this medicine. and this is a way we can do that more quickly, but also, we're trying to meet the needs of patients who don't have insurance coverage. >> reporter: but, to be clear, this won't help people who are on higher doses of zepbound. >> well, if they have coverage in their insurance, there's no change for them. if they don't have coverage with their insurance, they can talk to their doctor go moving to the five milligram dose. >> reporter: a former police officer is one of those patients paying $1100 a month. that's a lot of money a month. how are you able to do it? >> i'm putting it on credit cards, honestly. >> reporter: you're going into debt to take this medication. >> i am, yes. >> reporter: his doctor wants him on a higher dose starting next month.

elie honig, stick with us. we got a lot more to get to on this we want to go back to cnn's kaitlan poll answers continued digging through this kaitlan. what are you seeing right now? what stood out to you as you've had some more time with it, will fell as elie is saying, one of the things here is that the prosecutors really are trying to refocus this around the private things that donald trump was doing, either as a candidate or working with people who were private citizens at the time of the election and after the election. and one of the things that this refocusing of the charges looks like is that it focuses on how donald trump was using people in battleground states arizona, michigan, georgia, et cetera. to try and change the electoral votes or deceive the state people, the people in the legislators in those states one of the things too that the prosecutors have to do here is they have to be able to show how donald trump was doing this. and one way they want to do it is with his twitter account. now, they h

we've been talking so much about eli lilly, the clear leader, right?are index within the s&p is up 14% so far, so very respectable. let's bring in katie stockton, tech technician, and she has interesting thoughts whether we think names like eli lilly and novo nordisk, the ones that are anti-obesity, are the ones that will still be leading 6 to 12 months from now. katie? >> i think, dom, a shift in leadership is likely here. i say that in part for top-down reasons. when we sue market conditions develop, the winners, the leaders tend to be penalized in that environment. we are seeing for a seesaw corrections for the major indices. that would likely hit the likes of lilly and novo, harder than the laggards in that space. we've noticed some real recovery rallies to suggest they're on the verge of turning the corner. it comes at the same time we've seen very subtle loss of long-term up side. >> so you're not so much down on eli lilly, if i'm understanding you correctly, as saying eli lilly may get caught more than others in a market downdraft, that is a. b,

eli >> it's a step in the right direction, but i still have a lot of questions.l it for less, why don't they? >> reporter: eli lilly's announcement comes as compounding pharmacies are dispensing weight loss drugs they say are essentially a copy of zepbound, a cheaper option for patients. state licensed facilities like this one on long island are able to legally produce them because the fda has zepbound on a shortage list. some health care providers are recommending those versions for their patients, as long as they come from a trusted source, creating competition. eli lilly strongly opposes the practice. >> they're not inspected by the fda, they're not approved by the fda. in addition to that, you know, we invent the product. that's why there's a premium for the real thing made by lilly. >> stephanie joins us now in studio. so, stephanie, how much more difficult is it for the patients to give themselves the shots with the vials? >> well, there are other medications that use syringes, like insulin and fertility drugs, but it is definitely a little bit more difficu

see a markets share shift from eli lilly products in the united states.ome analysts are actually forecasting a 50/50 split between these two companies in terms of the market share in the united states. it is important to take a step back and also look at what other news we obtained in this space. recently, wegovy is less effective, i should say, than actually zepbound. let me share the numbers with you. patients that were on the highest dose of zepbound lost 21% of body weight over a period of 72 weeks. however, when you compare the results for wegovy patients, they lost 15% of body weight over a period of 68 weeks. so the efficacy here is important because it could change the reputation of novo's drugs in the united states. just a final point to say when you look at the share price reaction recently, both eli lilly shares and novo nordisk have also been hit by news that roche had seen positive trials for the weight loss pill. that would also be a huge change here for the weight loss drug market. i want to share this kpcomment with you when i had the chan

eli lilly announcing it will offer low-dosage versions of the weight loss drug in vials with syringesector pens that cost more than $1 $1,000 a month. now patients without insurance will be able to supply a 2.5 milligram dose for $399 and the 5 milligram dose for $549 directly from eli lilly. >> we have been frustrated. we can't meet the incredible demand for this medicine and it is a way we can do it more quickly, but also we are trying to meet the needs of patients who don't have insurance coverage. >> reporter: but to be clear, it won't help people who are on higher doses of zepbound? >> well, if they have coverage in their insurance, there's no change for them. if they don't have coverage with their insurance, they could talk to their doctor about moving to the 5 milligram dose. >> reporter: former police officer john keller is one of those patients paying $1,100 a month. that's a lot of money a month. how are you able to do it? >> i'm putting it on credit cards honestly. >> reporter: you are going into debt to take this medication? >> i am, yes. >> reporter: his doctor wants him

hims and hers down because of the eli lilly news as well. and eli litlly shares down a bi.ose shares go to a sell raying from a prior neutral and that target gets cut to 182. it was 195. they see a challenging year for pricing margins. we'll end with a check on ferrari. those shares are up fractionally, about half a percent. analysts at morgan stanley raising their target price on the high-end luxury carmaker to $520. it was $400. they keep the overweight rating. they're citing things like brand positioning with high-end customers, relatively low exposure to the chinese market and insulation from stalling out in vehicle sales. so ferrari shares one about a half a percent. for more on those and other big analyst calls of the day, just head over to cnbc.com/pro, joe. i will send things back over to you guys. >> thanks, dom. for more on the markets and earnings, let's bring in katherine kaminski, chief research strategist. at this point, katherine, the highs that we've seen in the dow, all-time highs, do the earnings and the underlying performance of the companies, cousin it j

we see that eli lilly shares are up today on better than expected results. and that's a contrast with nova which posted worse than expected results a couple days earlier and health care sector overall is one of the most anticipated in terms of earnings, this earnings season. if we look at sales beat across all of the s&p 500 sectors, we see that health care is the number one now. and the finally, retail sector, under armour sales are up by 19%. the company beat earnings expectations, boosted outlook across the world, it's a little bit mixed picture. so we see that sales in north america, they came above expectations. growth in asia is a little bit slow but some analysts are still very cautious even on north american market. now, let's take a finer look on the bigger picture again. and we can see that this chart shows the cost of protection against a 10% drop in the s&p 500, to be more specific, the largest e.t. that tracks the s&p 500, versus the cost of options that bet on rally, 10% rally in the s&p 500. so we now see that this cost of hedging against the

eli lilly said the move will increase consumers access to is about.sing the price of its flagship playstation 5 injapan by 19%. starting from september the second, the console will be sold for around $550. the company says it has been hit by a severe external environment. playstation 5 is around four years old and sales of the device fell in the most recent quarter. turning now to the uk where one company is trying to make budget flip phone is popular again. make budget flip phone is popularagain. hmd make budget flip phone is popular again. hmd says the features on its flip phone's could help parents trying to cope their children's access to harmful social media contents and they've tied up with barbie to make the phone is more appealing. the bbc is added looks at whether back to basic phones are the way forward. barbia, 65—year—old brand which was given a new lease of life last summer when the star—studded film hit cinemas is back again. this time, it's in the form of a flip phone made by the mobile phone company, hmd, the same budget brand behind n

dua lipa eli cohen he wants _ conflict in the region. cohen he wants to end _ conflict in the region. dua lipa eli cohen he wants to end this - conflict in the region. dua lipa eli cohen he wants to end this in - conflict in the region. dua lipa eli cohen he wants to end this in the j cohen he wants to end this in the near term # do you believe prime minister netanyahu wants to end this in the near term? this is nearly a year we are in the near term? this is nearly a yearwe are coming in the near term? this is nearly a year we are coming up to. do you believe that prime minister netanyahu believe that prime minister neta nyahu wants believe that prime minister netanyahu wants a deal and soon? it is a hard question. it is hard to read what is in his mind. i think he definitely once vast aegis back home. that isn't something i would question. similarly to what you just asked, does he want the wart to be over? i think he wants a deal to get the hostages, but i'm not certain once the water come to an end, because i think the war continuing d

i don't think so, robert eli fought for slavery and the civil war was for that reason, but some people think otherwise , the truth is that robert lee bought and sold men, women and children, all of robert's ancestors bought and sold people, but i am sure i say that it was the result of robert lee's actions. the number of casualties in america is very high. even i could not cope with the torment of his conscience. for this reason, in the last years of his life, he told others not to make a statue for him at all and not to sprinkle salt on his wound, and this caused discomfort. he was very adamant that this did not happen at all. clarice and stella are both descendants of those that my family had enslaved them. i want to know how they feel about this. my family, i have never talked to them about this , it is not comfortable for me to talk to these people about the slavery era, i don't like to upset them. anderson, i am clarice anderson, my mother was the nurse of this little girl, and my mother's mother had to. do the right thing , don't think too much about what your great grandfather d

i think eli -- injectable. i think eli will see m&a with the markets cap.y may purchase companies that have that technology. maria: depending on where you are in terms of the market, you're saying it's specific stories in second quarter earnings. >> like mark said a few months ago like a.i. or weight loss, that's been driving the market higher. >> look at krispy kreme. they cut guidance, right. i mean, so you look at all the health conscious decisions that are now coming from this glp-1 craze. it has an effect that really travels throughout the entire stock market. maria: we'll get weekly jobless claims this morning, 8:30 5*78 eastern, ebbing on miftszs are expecting 240,000 workers to file for unemployment. new survey finds three in five americans believe the u.s. is in he rec friends and family members continue to complain about money. we've got a market that is showing fear because of this worry about a slowing economy right now. >> yeah. it was very interesting, on monday when the fear gauge or the volatility index spiked up to 65 or so. maria: that was

eli lilly, ceo, spoke about the new options to nbc news. by adding vials today, we can expand supply for the lowest doses. the most commonly used doses two and a half and five milligrams. but also we're trying to meet the needs of patients who don't have insurance coverage if they have coverage in their insurance. there's no change for them. if they don't have coverage with their insurance and they're buying it out of pocket. they could talk to their doctor about moving to the five milligram dose. now you can watch more of that interview with eli lilly ceo coming up right now. and nightly news at 630. well, newly released census data is showing which cities in the united states are drawing the most lgbtq families. and san francisco tops the list. that's the census numbers from 2020. gay male couples tend to gravitate toward big cities on the coasts, while lesbian couples tend to prefer smaller cities and towns. san francisco had the largest share of male same sex couple households, at almost 6%. take a look. according to the data, just rele

the ceo of drugmaker eli lilly tells us about the company's announcement.hat could help some users. and we've got the right stuff for back to school. plus, tennis great andy roddick here giving us an insider's look at the u.s. open. and you will see this all on gma. >> you just really triggered an old memory of mine just by looking at that video of the albertsons, because it said osco pharmacy. which brings me back to chicago and jewel osco. >> yes, i lived right by a jewel parking lot, and i always walked past it and it's always in my head because i remember going to jewel for the first time. my stepdad is from chicago and being like, what is this? >> what is it? >> me too. we're so regional with our grocers. >> we really are. jewel osco is kind of the store if you live in the chicagoland area. okay and there was a osco. that was right by me. okay and there was a famous woman in there who would sing everything that you purchased until she would get the sensitive items, and then she would delete that. but it was so noticeable that she stopped singing that e

eli lilly said the move would increase us consumers' access to zepbound.mmer, barbie, the movie dominated the box office and popular culture. now, makers of the nokia phone, hmd global, have teamed up with toymaker mattel, to create, a barbie flip phone, as many parents grapple with how to give their children our technology editor, zoe kleinman has been taking a look. barbie, a 65—year—old brand which was given a new lease of life last summer when the star—studded film hit cinemas, is back again. hi, barbie! this time it's in the form of a flip phone made by the mobile phone company hmd, the same budget brand behind nokia. it's a feature phone, also sometimes called a dumb phone, meaning there's no access to social media and it can only perform basic functions like texting and calling. as concerns about the pressures of digital life on young people grows, hmd hopes devices like this might prove popular with children and indeed adults looking for a digital detox. i asked the firm whether the handset will live up to expectations among young people as it trie

but two is eli lilly. this morning lilly reported a quarter with 11.3 billion in sales when wall street was looking for less than 10 billion while raising their full year sales guidance to 46 billion. $3 billion above expectations. in large part thanks to these wondrous glp-1 drugs. it was a tour de force quarter, one where they highlighted so many different indications for mounjaro and depositionbound, those are different versions, same stuff, that you have to believe your insurance will cover it. it was also so good the insurers genuinely may not have a choice even if they need to pay through the nose for this stuff. lilly's results had nothing to do with mortgage rates or jay powell or a drug etf that might have capped your gains if you chose to play it that way. much better to just go with eli lilly, which is best in breed. it's not like nobody saw this coming. if you went with best in breed you were up 9.5% today. [ applause ] i know this morning i was very concerned that lilly could miss numbers, i t

but overall, jim, like you said, this is eli lilly's response to try to reach that high demand. that's out there, especially among patients who again, don't have the insurance coverage for this medication, but they don't qualify for the assistance program, so they are paying all the costs out of pocket. >> and do we think that some of these other pharmaceutical companies are going to try to follow suit and rollout these singer no dose vials. what do you think that's a great question. i think if we see that eli lilly is successful with this approach, i would not be surprised if other companies like the pharmaceutical companies behind semaglutide, like ozempic and wegovy follow suit, zepbound itself is a terse appetite weight loss drug, but the semaglutide are eating equally important. these include ozempic and wegovy and prescriptions specifically for semaglutide have gone up 40 fold in the past five years. jim. so that's the demand that we're seeing right now. and i will be interested to see what the future holds. if we do see other companies it's like you said, follow this same

brianna drug maker eli lilly is now offering cheaper single-dose vials of its popular weight loss drugszepbound. this might help with endless shrimp by the way, this is promising news for for anyone wanting to try the drug, but who can't afford it. eli lilly says the move single vials will actually allow for much greater supply of zepbound amid shortages brought on by its high popularity. we have cnn's jacqueline howard with us now on this story. all right, so how much is this going to cost? and who would qualify for a discount here well, brianna, this is specifically for patients who are paying the full out-of-pocket cost. >> and these are for patients who did not qualify for eli lilly's assistance program. now, how much these new starter doses will cost. we know that the for weeks supply for a supply of two 2.5 milligrams in each file that will be $399 a four-week supply of vials containing five milligrams will be $549. these costs are much lower than what the original list price was four is that bound, which was $1,059.87. so these are the differences were talking about here with the

jonathan: punchy upgrade, eli lilly had seen 42.4 to 43.6, the latest on eli lilly, up in the pre-markets surveillance this morning, when colleen turns to cold. >> looks to me that the labor market is cooling up significantly. every time that has happened, we get a recession, so there is a lot of risk out there. the problem here is on the market deteriorates, confidence declines, and that can be self reinforcing. jonathan: a light week of data has all eyes on jobless claims. estimate calling for 240,000 claims. sara wolf of morgan stanley saying the economy is on us soft landing -- soft landing path, writing that demand for labor is softening. the most recent payroll print showed a meaningful slow down, but the recent trend remains firmer. we expect and employment rate of 4.2% by q4 and 5.4% by the end of next year. sarah joins us for more. that is a constructive outlook when people are worried where this is going. where does that constructive outlook come from? sarah: the unemployment data is noisy. it is not the first time we've gotten a week payroll print around the hundred thousand ma

i sat down with eli lilly's ceo. who have been looking for a way to access and afford our weight loss medication zepbound. now they can go to lilly direct with a prescription from their doctor and phone, access the drug in a vial form. >> whit: the ceo dave ricks saying this will make the drug more available and affordable, allowing people to purchase it without insurance. >> we're working to build more supply but in the mean time we can release these vial forms that are 2 1/2 and 5 milligram dose that are going to be more available and at a lower price. about half the price of our auto injected form and the competitor products. this is launching at $349 for the low dose and $549 for the high dose. that's a significant discount. >> whit: you mean for a monthly amount? >> yes. >> whit: that's still a lot of money. people would be paying a lot. that's like a car payment for some people. can you explain why the cost is still so high? >> well, we're, of course, researching and developing medications. we invented this pro

and it's a window which novo nordisk and eli lilly argue. look, we develop these drugs, we should make some money in that period. we should benefit. i agree with them, but i would argue they don't need to make quite as much as they currently do. we could regulate them. you know, at the moment, novo nordisk is now the most profitable company in, the whole of europe. so i think we should be, you know, prioritizing, getting the drugs to people who need them, not least because by many measures, obesity is the killer in this country. professor mander at harvard, who the food label that's on all food the united states sold in the us. so explain to me, presented with his calculations that obesity and food related illnesses. kill 678,000 american boys every year that's more all the american soldiers who died in all the wars of the 20th century and indeed the war in this century and. i mean, that is a staggering toll. that's, you know, not far off having covid every year. the covid pandemic, every year. right. and that stock, we shouldn't accept this

we know eli lilly could be a competitor.his is a crucial time where you have to make investment decisions when prices are higher and you have more cash coming in. is that how you view it? lars: yes, to put a bit of color around it, the same forecast predicts that there will be one billion people living with obesity in 3035. we are perhaps serving one or 2 million of those today, so there's a huge market and there's a place for more, and then you are right that in most markets when you get more competition and also over time, pricing moves down because you start treating those who accept the higher price one in the u.s. and that's commercial insurance and then you get broad access and you get your patient's payload price. so, if you just take our leading diabetes product in the u.s. since launch, in 2018, the price we get is some 40% lower than when we launched. that's also not mentioned in the politics. instead the list price is mentioned. which is what we put in our account. francine: the u.s. is such a large market would y

louis, cnn political commentator, and also a host on spectrum news elie, does this have any merit? >> know, this has no chance whatsoever. this is a political stunt, masquerading as the beginning of a lawsuit. let me just give you a couple of problems. first of all, immunity. all right. it is really hard to sue a federal agency or a federal official. now, trump is the beneficiary of immunity in his criminal case. but here, immunity is going to be a big problem for him in suing. >> the other thing is he's got nothing. this search had more than enough probable cause. a federal judge's signed off and i'll give you a couple of quick examples from the actual filing that are so ridiculous. first of all, he claims that he would have turned over the documents if he was just asked nicely and you know what he cites to support that his own on truth social and says, see, i would have done it. the other thing is, he says, well, the law says that the fbi has to ask for permission before they do a search warrant mean that's as ridiculous as it sounds. the reason you do a search warrants because y

certainly not before the election, but elie walk us through what the next steps are here. what we see donald trump go back to play again. >> yeah, so now they fight it out in court. i'm sure donald trump, when he goes into court next week will say, we still think a lot of the stuff that's in the indictment is immune and shut and come out. jack smith obviously will defend his indictment. and judge chutkan has to sort that out. she can either hear from the lawyers in written briefs or she can hold a hearing which might look like a mini trial to decide what's in and what's out. and as john said, from there, donald trump will have the right to appeal to the court of appeals, the intermediate court of appeals, and then potentially the supreme court. so 0.0% chance this thing gets tried before the 2024 election. >> and john, just yesterday, jack smith filed an appeal to bring back the classified documents case. now he's filing the superseding indictment to save the election interference case do you think he's sending a signal here that he's going to keep up the fight i think it'

he said: robert ely is one of our great ancestors who led the federal army in the american civil war has been in charge i was proud of this great ancestor until i realized that this person fought to support slavery. in 2017 , there were protests in the city of shrewsfield in our state, which shocked everyone. in this city , there was a neighborhood named robert ely, my grandfather, whose name was changed at the request of the city council. it was found and the statue of my grandfather was supposed to be removed from there, but hundreds of people who believe that white people are the superior race started a demonstration and opposed this action. these adventures made me understand for the first time who my ancestors were who were slaves. now i want to know why the people and my fellow citizens of virginia have nothing in common with regard to the monuments and monuments of the confederate state. i want to understand. to what extent has the oppression of slaves by my ancestors affected the lives of blacks in america today? how come richmond , virginia was the former capital of the conf

eli lilly says this version of bound will help with the increased demand for weight loss medications. and later this morning on gma, abc news anchor whit johnson talks one on one with eli lilly ceo david ricks to discuss the direct to consumer version of bound. you can watch the full interview at 7:00, right after abc seven mornings. >> thanks, amanda. 507 this morning we're in store for another warm to hot day. today's the hottest day on the seven day forecast. warm sunshine in the city today will hit 74. 84 in oakland today. sunny and hot in the south bay. 93 in san jose. it's a hot august day in walnut creek hitting about 97 with those sunny skies. hello okay, a live look at the airport this morning. you could see it is quiet out there. we have clear skies above the airport. 59 degrees right now in oakland. great visibility, high humidity and the winds are very light. so let's take a look at the travel forecast. it is warm across our desert today 109 in phoenix, 103 in vegas to the north in the pacific northwest seattle. some morning showers giving way to sunshine, a high of 67 deg

. >>> drugmaker eli lilly is slashing the price of weight-loss drug zepbound for single-use vials instead injector pen. the company says this will allow it to expand supply and give patients whose insurance doesn't cover the drug a safe and effective treatment on option. the single-use vials will only be available on the eli lilly telehealth platform lilly direct. >>> policy changes at lowe's. the home improvement company scaling back its diversity, equity, and inclusion policies. it comes after several other companies recently did the same. the change has been in response to the supreme court's decision to outlaw affirmative action in college admissions and a wave of conservative backlash on line. >>> and pizza hut is trying to make your next move a little easier. the restaurant chain is now offering customers a free moving box table. it's a mini cardboard table which you can rest your pizza on. the limited time offer is only available to customers in dallas, charlotte, and orlando. >>> that's your cbs "moneywatch" report for this wednesday morning. i'm shanelle kaul, cbs news, new york.

also, according to director eli roth, blockbuster has many references not only to the computer game, but to the fifth element, star wars, mad max and other cult hits, so for connoisseurs of the genre, the film will be a special pleasure. such films are interesting because they force people who have nothing in common to cooperate. in our film , the bandits, the mercenary, and the robots, they are all forced to learn to rely on each other to achieve. the main goal of our film. according to forecasts of the film industry, borderland will become the leader of the russian film distribution this week. during pre-sales, the film mastered about 3.5 million rubles. which is lower than the figures for the ministry of ungentlemanly affairs of bad boys forever, but gives the opportunity to calculate the collections of 100-150 million for the first weekend. i think it will be very cool to get together in the cinema and go on this large-scale, daring, positive journey. i really hope that people will penetrate. the atmosphere of this film, i will immediately run to the cinema and enjoy it in a dark

eli lilly powering higher on the strength, of course, of its glp-1s.r hannifin and cf. >> oh, fantastic. >> you can catch us any time, anywhere, by the way, if you listen to and follow the "squawk on the street: opening bell" podcast. okay, team! oh, thank you so much i couldn't have done it without you. honestly, i don't do a whole lot here. i'm really just here for the at&t internet, it's super-fast so, any pre-launch concerns? what if nobody buys them? that's mean or, what if everybody buys them? oh, i hadn't thought of that that's probably not gonna happen can we handle that kind of traffic? the network can handle it! i downloaded eight hours of true crime stories just during our last video call i'm learning a lot >> announcer: the opening bell is brought to you by nuveen, a leader in income, alternatives, and responsible investing. >>> let's get to a "mad dash." opening bell a minute and a half from now. robinhood? >> now, lilly is overshadowing everything else, but people have to take a hard look at robinhood, because this stock will be up more t

now, among the new releases , eli roth's fantastic action film borderlands, which was filmed based on the video game series of the same name, has been released on russian screens. the leading role is played by the acrobatic actress cate blanchett. you can't help it, run, run, red-haired beauty lelith is the most successful bounty hunter in the entire universe, so when a powerful arms dealer's daughter is kidnapped, lilith is tasked with finding her. however, the mission turns out to be impossible. the girl's trail leads to the planet pandora, which has long since turned into a huge garbage dump where only mutants and monsters survive. nevertheless, lilith takes on the task... she understands that in order to save the lost girl , she must find a storage facility in which representatives of an ancient civilization have hidden unique technologies, and help her with this a team of freaks is taken. you have no idea how many people died looking for this vault. we have something they didn't have, grandpa. so what? we're frozen. it's going to rain your carcasses now. what did i tell you? the

we know of eli lilly. we know amgen could be a competitor.nd so this is, i guess, the crucial time when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 3035. we are perhaps serving one million or two million of those today. so, there is a huge market opportunity, and there is a place for more. and then, you're right, that in most markets when you get more competition, and also over time, pricing starts moving down, because you start treating those who accept, say, the higher price point -- in the u.s., that's commercial insurance -- and then, over time, you get broader access, and you get patients paying a lower price. so if you just take our leading diabetes product in the u.s., since launch in 2018, the price we get after rebates, discounts, etc. is some 40% lower than when we launched. that is often not mentioned in, say, the political

. >> novo nordisk in eli lilly had the blockbuster drugs in a recent study out of uk suggested an olderlp-1 drug novo could slow the progression of alzheimer's disease. his noxious weight loss, there's more research out of the uk, we showed that the shingles vaccine may delay the onset of dementia as well, do the relatively small studies in incremental results but alzheimer's is a devastating disease and people are paying attention and looking for help. meanwhile the adjacent sector of biotech as had a really bad few years, what is going on you see signs of hope? >> it's been terrible if you look at xpi or biotech ets over the last five years up about 15% and 65 percentage points it's been a terrible sector, it's more of a rate trade biotech's are speculative stocks in as a drug works there is a lot of smaller capitalization into thirds of the biotech stocks lose money and below 5 billion at the speculative sector, when rates go down it is cheaper to speculate. jack: you recommend the index rather than trying to pick winners and losers. >> you can even, aaron judge hits a homerun 8% of

ademÁs, la versiÓn de pound, que estÁ lanzando eli lilly elimina las plumas auto inyectoras de dosisivienda. los precios de las casas en todo el paÍs alcanzaron cifras rÉcord con un aumento a nivel nacional del 5.4% con respecto a junio de 2023 y con un precio promedio de 362.000 $. la situaciÓn tambiÉn es grave para los inquilinos. en promedio, a nivel nacional se gastan mÁs del 27% de los ingresos familiares en pagos de renta. ciudades como nueva york, miami y los Ángeles encabezan la lista de los alquileres mÁs costosos. sonia aparicio sÁnchez amplÍa la informaciÓn porque se estÁ sobrepasando el lÍmite. >> ingrid vÉlez por fin, despuÉs de muchos aÑos en los estados unidos, pudo comprar su casa en el sur de la florida. sin embargo, segÚn ella, el remedio resultÓ peor que la enfermedad afecta su bolsillo muchÍsimo, porque realmente hay muchas cosas. >> no es solo pagar la renta de tu casa o el mortgage viene. tienes que pagar luz, tienes que pagar agua. >> el estudio realizado por moody's analytics analizÓ los precios en cinco grandes ciudades desde el 2019 y encontrÓ que las vivien